Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

• ClinicalTrials.gov Identifier: NCT03113266
• Recruitment Status: Unknown
• First Posted: April 13, 2017
• Last Update Posted: September 30, 2020
• Sponsor: Shanghai Junshi Bioscience Co., Ltd.
• Information provided by (Responsible Party): Shanghai Junshi Bioscience Co., Ltd.

Study Description

Brief Summary:

This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial carcinoma who have failed in routine systemic treatment.

Condition or disease	Intervention/treatment	Phase
Bladder Urothelial Carcinoma	Biological: humanized anti-PD-1 monoclonal antibody toripalimab	Phase 2

Detailed Description:

This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial carcinoma who have failed in routine systemic treatment.The implementation of study meet the GCP.370 patients will be enrolled in the study to evaluate the safety and efficacy of JS001.Patients are injected with JS001 with 3mg/kg every 2 weeks until disease progresses or unacceptable toxicity occurs.Response assessment is conducted by every 8 weeks in first year, every 12 weeks in second year and every 16 weeks in third year and beyond.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 370 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
• Actual Study Start Date: April 6, 2017
• Actual Primary Completion Date: March 15, 2020
• Estimated Study Completion Date: February 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: humanized anti-PD-1monoclonal antibody; humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs	Biological: humanized anti-PD-1 monoclonal antibody toripalimab; humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.; Other Name: JS001, TAB001

Outcome Measures

Primary Outcome Measures :

1. Objective response rate (ORR) by RECIST 1.1 and irRECIST [ Time Frame: 3 years ]
   The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine tumor response.

Secondary Outcome Measures :

1. Duration of response (DOR) by RECIST1.1 and irRECIST [ Time Frame: 3 years ]
   The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine duration of response.
2. Progression free survival (PFS) by RECIST1.1 and irRECIST [ Time Frame: 3 years ]
   The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine progression-free survival time.
3. Overall survival (OS) [ Time Frame: 3 years ]
   The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine overall survival.
4. Immunogenicity of anti-PD-1 monoclonal antibody [ Time Frame: 3 years ]
   To test immunogenicity of anti-PD-1 monoclonal antibody
5. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 3 years ]
   Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Other Outcome Measures:

1. Correlation analysis of PD-L1 expression of tumor by ORR [ Time Frame: 3 years ]
   correlation analysis of PD-L1 expression of tumor and objective response rate
2. Correlation analysis of PD-L1 expression of tumor by Immunohistochemistry [ Time Frame: 3 years ]
   to analyse PD-L1 expression of tumor by Immunohistochemistry

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male and Female aged 18 and older are eligible;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Histologic diagnosis of locally advanced or metastatic bladder urothelial carcinoma, including the origin of renal pelvis, ureter, urinary tract;
• At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);
• Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);
• Predicted survival >=3 months;
• Brain or meningeal metastases must be disposed with surgery or radiation, and be stable clinically for at least 3 months (prior systemic steroids was allowed, but concurrent administration of systemic steroids with the study drug is excluded).
• Screening laboratory values must meet the following criteria（within past 14 days）:

hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ µL; platelets ≥ 100 x 10^3/ µL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN，creatinine clearance >50ml/min (Cockcroft-Gault equation) INR, aPTT≤1.5 x ULN; Urine protein + 1 or less, if the urine protein > 1 +, need to collect 24 hours urinary protein determination, the total amount should be 1 gram or less

• Without systemic steroids within past 4 weeks
• Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.
• Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

• Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody, including auxiliary treatment phase
• Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components
• Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
• Pregnant or nursing;
• Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml);
• HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml)
• History with active tuberculosis;
• Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism;
• Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
• Evidence with active CNS disease;
• Prior live vaccine therapy within past 4 weeks;
• Received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
• Prior major surgery within past 4 weeks (diagnostic surgery excluded);
• Psychiatric medicines abuse without withdrawal, or history of psychiatric illness;
• Associated with clinical symptoms or symptomatic treatment of pleural effusion or ascites;
• Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix.
• Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.

Contacts and Locations

Contacts

Contact: Ling Xiao; 051286876925; ling_xiao@topalliancebio.com

Locations

China, Beijing

Beijing Cancer Hospital; Recruiting

Beijing, Beijing, China, 100142

Contact: Jun Guo, Phd; Md guoj307@126.com

Principal Investigator: Jun Guo, PhD; MD

Sponsors and Collaborators

Shanghai Junshi Bioscience Co., Ltd.

Investigators

• Principal Investigator: Jun Guo; Peking University Cancer Hospital & Institute

More Information

• Responsible Party: Shanghai Junshi Bioscience Co., Ltd.
• ClinicalTrials.gov Identifier: NCT03113266
• Other Study ID Numbers: Junshi-JS001-009
• First Posted: April 13, 2017
• Last Update Posted: September 30, 2020
• Last Verified: September 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shanghai Junshi Bioscience Co., Ltd.:

anti-PD-1 monoclonal antibody; Metastatic; Advanced; Bladder Urothelial Carcinoma

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Transitional Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Antibodies; Antibodies, Monoclonal; Immunologic Factors; Physiological Effects of Drugs